- Home
- REGN
as 12-20-2024 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 110.0B | IPO Year: | 1991 |
| Target Price: | $1054.00 | AVG Volume (30 days): | 851.0K |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 40.43 | EPS Growth: | 15.31 |
| 52 Week Low/High: | $693.00 - $1211.20 | Next Earning Date: | 01-31-2025 |
| Revenue: | $13,847,100,000 | Revenue Growth: | 5.72% |
| Revenue Growth (this year): | 10.2% | Revenue Growth (next year): | 4.16% |
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCourt Marion | REGN | EVP Commercial | Nov 1 '24 | Sell | $844.61 | 1,000 | $844,610.00 | 12,931 | |
| McCourt Marion | REGN | EVP Commercial | Oct 1 '24 | Sell | $1,054.06 | 1,000 | $1,054,060.00 | 12,931 | |
| RYAN ARTHUR F | REGN | Director | Oct 1 '24 | Sell | $1,049.73 | 100 | $104,878.24 | 17,673 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
MT Newswires
2 days ago
Regeneron Says Investigational Antibodies Show Antithrombotic Effects in Phase 2 Trial
BioPharma Dive
2 days ago
Regeneron says study data support big bet on new blood thinners
GlobeNewswire
2 days ago
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Morningstar Research
3 days ago
Analyst Report: Regeneron Pharmaceuticals, Inc.
Zacks
3 days ago
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Zacks
3 days ago
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
GlobeNewswire
4 days ago
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.